Explanation to Bollinger's Bands
Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.
Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.
Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation
BandWidth defines the current width of the band.
%b defines the current position within the band.
BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)
Bottlenecks in bandwidth indicates a upcoming change. Break up through the moving average line, or continuously movements above the moving average line indicates a break up, and vice versa downwards.
Red day on Friday for BioShares Biotechnology Clinical Trials
(Updated on Jan 21, 2022)
Sell candidate since 2021-12-27 Loss -26.25% PDF
The BioShares Biotechnology Clinical Trials fund price fell by -2.35% on the last day (Friday, 21st Jan 2022) from $29.93 to $29.22. and has now fallen 4 days in a row. During the day the fund fluctuated 2.45% from a day low at $29.22 to a day high of $29.94. The price has fallen in 7 of the last 10 days and is down by -17.48% for this period. Volume has increased on the last day by 2 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 4 thousand shares were bought and sold for approximately $126.80 thousand.
The fund has broken the wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($31.34) are considered to be a "second chance" to get out. According to the fan-theory $26.40 will represent the new bottom line of the next trend, but it is far too early to say this for certain.
Signals & Forecast
There are few to no technical positive signals at the moment. The BioShares Biotechnology Clinical Trials fund holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $31.48 and $36.94. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, December 23, 2021, and so far it has fallen -28.15%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). BioShares Biotechnology Clinical Trials gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the fund may perform very badly in the next couple of days.
This fund may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this fund is considered to be "high risk". During the last day, the fund moved $0.72 between high and low, or 2.45%. For the last week, the fund has had a daily average volatility of 3.30%.
BioShares Biotechnology Clinical Trials is oversold on RSI14 (14). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.
Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.
Is BioShares Biotechnology Clinical Trials Fund fund A Buy?
BioShares Biotechnology Clinical Trials holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this fund.
Current score: -6.634Strong Sell Candidate Unchanged
Predicted Opening Price for BioShares Biotechnology Clinical Trials Fund of Monday, January 24, 2022
The predicted opening price is based on yesterday's movements between high, low, and the closing price.
|Fair opening price January 24, 2022||Current price|
Remember To Visit Our YouTube Channel
Fibonacci Support & Resistance Levels
Accumulated Volume Support & Resistance Levels
Click to get the best stock tips daily for free!
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 100 000+ Happy SubscribersDon't miss out on the runners!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.